Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several statements about Lipitor’s class/indication rationale and some adverse reaction content are partially supported, but many adverse effect and interaction claims are unsupported or overstated relative to the provided label excerpts (e.g., “most common” lists and non-labeled effects like constipation, vomiting, dizziness, dehydration, dehydration-related effects). Overall alignment is limited.
Category Scores
Accurate Statements
Lipitor is a statin medication.
12 CLINICAL PHARMACOLOGY context indicates LIPITOR is an HMG-CoA reductase inhibitor (a statin).
Lipitor (atorvastatin) belongs to the class of medications called statins.
12 CLINICAL PHARMACOLOGY indicates selective, competitive inhibitor of HMG-CoA reductase; statins are described throughout label (e.g., warnings section).
Statins work by blocking the production of cholesterol in the liver.
12 CLINICAL PHARMACOLOGY indicates inhibition of HMG-CoA reductase (mechanism consistent with reducing cholesterol synthesis).
The most common adverse reactions include muscle pain or weakness (myalgia).
6.1 Clinical Trial Adverse Experiences: myalgia (0.7%) is listed among the five most common adverse reactions leading to discontinuation.
Muscle damage caused by Lipitor can lead to muscle pain.
5.1 Skeletal Muscle: occasional myopathy; 6 overview discusses rhabdomyolysis and myopathy; label links serious muscle events with muscle symptoms.
Muscle damage caused by Lipitor can lead to muscle weakness.
5.1 and 6 discuss myopathy/rhabdomyolysis as muscle adverse reactions (symptoms include weakness in clinical context), but specific weakness wording is not explicitly shown in provided excerpts.
Lipitor can cause inflammation in the muscles.
5.1 discusses myopathy (muscle disorder) but provided excerpts do not explicitly use the term 'inflammation'.
Lipitor can interact with other medications.
7 DRUG INTERACTIONS: risk of myopathy increased with certain concurrent drugs.
The risk of myopathy during treatment with statins is increased with concurrent administration of cyclosporine or strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, itraconazole).
7 DRUG INTERACTIONS and 5.1 Skeletal Muscle.
Unsupported Statements
Lipitor (atorvastatin) is used to treat high cholesterol.
Provided indication excerpts describe reducing risk in specific cardiovascular contexts and lowering lipid parameters with adjunct to diet; 'treat high cholesterol' is not explicitly phrased in the excerpts.
Lipitor (atorvastatin) is used to treat high triglycerides.
Label excerpts state treatment of patients with elevated serum TG levels (Fredrickson Type IV) as adjunct to diet, but the statement is not an exact label phrase; still generally consistent—however it is not explicitly stated in the excerpt as 'high triglycerides' without qualification.
Statins work by blocking the production of cholesterol in the liver.
Mechanism excerpt provided is HMG-CoA reductase inhibition; the specific claim about 'in the liver' is not explicitly stated in the provided excerpt.
The most common side effects of Lipitor include muscle cramps.
Provided 'five most common adverse reactions' excerpt lists myalgia, diarrhea, nausea, ALT increase, hepatic enzyme increase; muscle cramps are not listed there.
The most common side effects of Lipitor include muscle fatigue.
Fatigue appears in postmarketing experience list (6.2) but not among the 'five most common' clinical trial adverse reactions excerpted.
The most common side effects of Lipitor include muscle tenderness.
Not listed in provided 'five most common' clinical trial adverse reactions or other excerpts.
The most common side effects of Lipitor include joint pain.
Arthralgia is listed as commonly reported (≥2%) but not explicitly identified as 'most common side effects' in the provided excerpts.
The most common side effects of Lipitor include headache.
Headache is not listed in the provided 'five most common' excerpt or commonly reported list excerpt.
The most common side effects of Lipitor include abdominal pain.
Abdominal pain is not listed in the provided 'five most common' excerpt.
The most common side effects of Lipitor include vomiting.
Vomiting is not listed in the provided excerpts.
The most common side effects of Lipitor include diarrhea.
Diarrhea is included (0.5%) among five most common leading to discontinuation, but statement uses broad 'most common side effects' framing without matching the exact excerpt wording.
The most common side effects of Lipitor include constipation.
Constipation is not listed in provided excerpts.
The most common side effects of Lipitor include fatigue.
Fatigue is listed in postmarketing experience, not in the provided 'five most common adverse reactions' clinical trial excerpt.
The most common side effects of Lipitor include dizziness.
Dizziness is listed in postmarketing experience, not in the provided 'five most common' clinical trial excerpt.
Lipitor can cause muscle damage.
Label excerpts discuss myopathy/rhabdomyolysis; 'muscle damage' is not an explicit label phrase in the provided excerpts.
Muscle damage caused by Lipitor can lead to muscle cramps.
Cramps are not explicitly supported in the provided excerpts.
Lipitor can cause inflammation in the joints.
Label excerpt lists arthralgia and myopathy; it does not explicitly describe 'inflammation in the joints'.
Lipitor can cause inflammation in other tissues.
Not supported by provided excerpts.
Inflammation caused by Lipitor can lead to pain and discomfort.
Inflammation is not explicitly described in label excerpts; provided evidence for generic pain/discomfort is not specific enough.
Lipitor can cause dehydration.
Dehydration is not mentioned in provided adverse reaction excerpts.
Dehydration caused by Lipitor can lead to fatigue.
Dehydration is not supported by provided excerpts; causal linkage not supported.
Dehydration caused by Lipitor can lead to headaches.
Dehydration and headache not supported in provided excerpts.
Dehydration caused by Lipitor can lead to muscle cramps.
Dehydration and muscle cramps not supported in provided excerpts.
Lipitor interacts with blood thinners.
Blood thinners are not named in the provided drug interaction excerpts.
Lipitor interacts with antibiotics.
Only specific examples (clarithromycin) are mentioned; 'antibiotics' broadly is not supported by provided excerpts.
Lipitor interacts with antifungals.
Only itraconazole is explicitly mentioned; 'antifungals' broadly is not supported by provided excerpts.
Interactions of Lipitor with other medications can lead to side effects.
General interaction risk is supported, but statement is overly broad and not tied to label-specified outcomes in provided excerpts.
Contradictions
Low
AI Statement
Lipitor can cause dehydration.
Label Reference
No dehydration adverse reaction or warning is stated in provided label excerpts.
Important Omissions
Specific boxed warnings are not addressed (none provided in excerpts). Also, pregnancy contraindication details and lactation guidance are omitted from the AI response.
Importance:
Moderate
Label-recommended dosing range and administration timing (10–80 mg once daily; can be taken with or without food) are not provided despite being a dosage question area.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response includes multiple unsupported or overly broad adverse-effect and interaction claims (e.g., dehydration, blood thinners/antibiotics/antifungals broadly, constipation/vomiting/headache framed as 'most common'). While no direct contraindication or dosing instructions are provided, inaccurate safety expectations could mislead monitoring or risk perception.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Many adverse reaction statements and drug interaction claims are not supported by the provided FDA label excerpts, and several are framed as 'most common' without matching the label’s enumerated common adverse reactions.
Suggested Improvement
Restrict adverse reaction and 'most common' lists to the exact label-provided adverse reaction entries (e.g., myalgia, diarrhea, nausea, ALT/enzymes increases) and name only specific interacting drugs/classes included in the label excerpts (e.g., cyclosporine and strong CYP3A4 inhibitors such as clarithromycin/itraconazole). Provide label-supported indications and dosing statements verbatim or closely paraphrased from the provided sections.